Strategic Acquisition Berry & Company has been acquired by CG Life, signaling expanded strategic communications capabilities and increased scale in biopharma and healthcare markets. This presents cross-sell opportunities for CG Life’s broader service suite and potential integration into a larger client portfolio.

Biopharma Focus Specialization in communications for products and information that protect or improve health, with experience supporting over 60 FDA approvals and 300 research programs. Target opportunities with pharma, biotech, and medical device clients seeking end-to-end PR from preclinical to post-approval.

Financial Scope Reported revenue range of 1M to 10M and a lean team size, indicating opportunities to upsell higher‑value, comprehensive programs, crisis/comms readiness, and expanded digital/paid media services to mid-market life science firms.

Existing Client Loyalty More than half of clients have been with the firm for five years or longer, suggesting a stable relationship base and potential for expansion through tiered retainers, added services, and more frequent retainers with existing accounts.

Technology & Compliance Tech stack includes WordPress, security measures, and performance tools, pointing to opportunities to offer digital content optimization, website governance, and scalable analytics to enhance client programs and ensure regulatory‑compliant digital PR assets.